EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
- 31 October 2004
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 40 (15), 2201-2216
- https://doi.org/10.1016/j.ejca.2004.07.015
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant diseaseCancer, 2003
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Erythropoietin therapy: Is there a place in advanced prostate cancer-related anemia?European Journal Of Cancer, 2001
- Early intervention with epoetin alfa treats anaemia and improves quality of life in ovarian cancer patients undergoing chemotherapyEuropean Journal Of Cancer, 2001
- Erythropoietin reduces anemia and transfusionsCancer, 1999
- Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancerBritish Journal of Cancer, 1999
- Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapyMedical Oncology, 1998
- Prevention of chemotherapy‐induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double‐blind, randomized, phase III study)Transfusion, 1996
- Erythropoietin Treatment of Anemia Associated with Multiple MyelomaNew England Journal of Medicine, 1990
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986